The effect of recombinant human growth hormone on wound healing in normal individuals.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

This study was undertaken to determine the effect of recombinant human growth hormone on the rate of wound healing in normal individuals.

Why It Was Studied

Each subject received a split-thickness wound (Davol-Keratome) on one buttock and a full-thickness wound (3-mm punch biopsy) on the other.

Who Took Part

By PubMed's age tags, the people studied were teenagers, adults and middle-aged adults, men only.

Twenty-three healthy males were evaluated in a randomized, double-blind placebo-controlled study.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

Topics PubMed links to this paper include Growth Hormone, Human Growth Hormone, Recombinant Proteins, Skin and Wound Healing.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1991 (The Journal of dermatologic surgery and oncology), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.